These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 12679126)

  • 21. Fondaparinux sodium.
    Reverter JC
    Drugs Today (Barc); 2002 Mar; 38(3):185-94. PubMed ID: 12532174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis.
    Bauer KA
    Am J Orthop (Belle Mead NJ); 2002 Nov; 31(11 Suppl):4-10. PubMed ID: 12463577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies.
    Turpie AG; Eriksson BI; Bauer KA; Lassen MR
    Chest; 2003 Dec; 124(6 Suppl):371S-378S. PubMed ID: 14668420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fondaparinux: use in thromboprophylaxis of acute medical patients.
    Dhillon S; Plosker GL
    Drugs Aging; 2008; 25(1):81-8. PubMed ID: 18184032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology.
    Bauer KA
    Chest; 2003 Dec; 124(6 Suppl):364S-370S. PubMed ID: 14668419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short- and long-acting synthetic pentasaccharides.
    Koopman MM; Büller HR
    J Intern Med; 2003 Oct; 254(4):335-42. PubMed ID: 12974872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fondaparinux sodium.
    Keam SJ; Goa KL
    Drugs; 2002; 62(11):1673-85; discussion 1686-7. PubMed ID: 12109927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spotlight on fondaparinux sodium in acute coronary syndromes.
    Blick SK; Orman JS; Wagstaff AJ; Scott LJ
    BioDrugs; 2008; 22(6):413-5. PubMed ID: 18998758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of symptomatic venous thromboembolism: improving outcomes.
    Büller HR
    Semin Thromb Hemost; 2002 Jun; 28 Suppl 2():41-8. PubMed ID: 12073179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Setting a standard for venous thromboembolism prophylaxis.
    Turpie AG
    Am J Health Syst Pharm; 2001 Nov; 58 Suppl 2():S18-23. PubMed ID: 11715835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pentasaccharides. The new anticoagulants.
    Abdel-Razeq H
    Saudi Med J; 2004 Aug; 25(8):983-90. PubMed ID: 15322584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery.
    Andersen JC
    Semin Thromb Hemost; 2004 Dec; 30(6):609-18. PubMed ID: 15630666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fondaparinux: an update on new study results.
    Bauersachs RM
    Eur J Clin Invest; 2005 Mar; 35 Suppl 1():27-32. PubMed ID: 15701145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fondaparinux sodium: a review of its use in the management of acute coronary syndromes.
    Blick SK; Orman JS; Wagstaff AJ; Scott LJ
    Am J Cardiovasc Drugs; 2008; 8(2):113-25. PubMed ID: 18422394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fondaparinux: a new antithrombotic agent.
    Cheng JW
    Clin Ther; 2002 Nov; 24(11):1757-69; discussion 1719. PubMed ID: 12501872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short- and long-acting synthetic pentasaccharides as antithrombotic agents.
    Walenga JM; Jeske WP; Fareed J
    Expert Opin Investig Drugs; 2005 Jul; 14(7):847-58. PubMed ID: 16022574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factor Xa inactivation in acute coronary syndrome.
    Barantke M; Bonnemeier H
    Curr Pharm Des; 2008; 14(12):1186-90. PubMed ID: 18473865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux.
    Turpie AG
    Surg Technol Int; 2004; 13():261-7. PubMed ID: 15744699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterogeneity of synthetic factor Xa inhibitors.
    Gerotziafas GT; Samama MM
    Curr Pharm Des; 2005; 11(30):3855-76. PubMed ID: 16305517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.